| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

23 January 2025

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

21 January 2025

ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

13 January 2025

ORYZON announces first patient dosed in NCI-sponsored iadademstat in combination with venetoclax and azacitidine clinical trial in first line acute myeloid leukemia

25-27 February 2025

Bio-Neurosciences 2025

Hotel Jakarta

Amsterdam

Netherlands

13 February 2025

MidCap Events Frankfurt 2025

Steigenberger Icon Hotel

Frankfurt

Germany

4 February 2025

Invest Securities BioMed Forum 2025

Salons Hoche

Paris

France

13-15 January 2025

14th Annual LifeSci Advisors Corporate Access Event

Beacon Grand Hotel in San Francisco

CA

United States

12 January 2025

8th Sachs Annual Neuroscience Innovation Forum

Marines’ Memorial Club in San Francisco

CA

United States

9 January 2025

ORYZON to provide corporate progress updates at several events in January-February

2 December 2024

ORYZON continues to strengthen its patent portfolio for vafidemstat

Pagination

First page «
Previous page ‹
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel